Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
How did MBAI's recent EPS compare to expectations?
The most recent EPS for Check Cap Ltd is $, expectations of $.
How did Check Cap Ltd MBAI's revenue perform in the last quarter?
Check Cap Ltd revenue for the last quarter is $
What is the revenue estimate for Check Cap Ltd?
According to of Wall street analyst, the revenue estimate of Check Cap Ltd range from $ to $
What's the earning quality score for Check Cap Ltd?
Check Cap Ltd has a earning quality score of B+/48.17516. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Check Cap Ltd report earnings?
Check Cap Ltd next earnings report is expected in 2026-03-30
What are Check Cap Ltd's expected earnings?
Check Cap Ltd expected earnings is $, according to wall-street analysts.